Outpatient Asthma Management 0 - 4 Years Old



Make the Diagnosis

- Consider the diagnosis of asthma if symptoms include recurrent coughing, wheezing or shortness of breath relieved by a bronchodilator
- Consider co-morbidities or alternate diagnosis, especially if poor control: GERD, aspiration, airway anomaly, foreign body, cystic fibrosis, anxiety, vocal cord dysfunction, tobacco/secondhand smoke exposure, or COPD. GERD is a common co-morbidity
- If diagnosis is in doubt, consult with asthma specialist



Key points of Assessment and Treatment

- Asthma is a variable disease and needs to be assessed at every visit
- Use the Assess Asthma Control box to guide your assessment and make treatment decisions
- The goal of asthma therapy is to keep the patient in control as much as possible with the least amount of medication
- If at the first visit the patient is not well-controlled (see below), begin controller therapy. A patient

should be diagnosed with persistent asthma if he/she needs a daily controller medication to stay in control.

Exercise-Induced Bronchospasm (EIB)


- If symptoms resolve without treatment after 5 minutes of rest, it is more likely poor conditioning.
- If EIB is unresponsive to albuterol and the patient has allergies, consider starting an inhaled steroid (see Stepwise Treatment Table)
- If still unresponsive after starting albuterol, refer to specialist
- -Pretreat

Asthma Control Test (ACT)		Well-Controlled (Yes 3/5) Score of ≥ 20	Not Well-Controlled (Yes 3/5)	Very Poorly Controlled (Yes 5/5) Score of ≤ 15
			Score of 16 - 19	
OR A	Assess all the Below:	ı	,	
1. D	aytime Symptoms	≤ 2 days/week	> 2 days/week	Throughout the day
2. N	lighttime Awakenings	≤1 time/month	>1 time /month	>1 time/week
3. Li	imitation of Activities	None	Some limitation	Extremely limited
S	hort-Acting beta2-agonist use for ymptom control (not prevention of IB)	≤ 2 days/week	> 2 days/week	Several times per day
5. C	ourses of prednisone in last year	0-1 per year	2 or 3 times per year	>3 times per year

If Well Controlled:	If Not Well Controlled:	If Very Poorly Controlled:
Follow the Stepwise Approach	Follow the Stepwise Approach	Consider short course of oral
Guideline (see page 2). Consider	Guideline. If initial visit, start at	prednisone for 3 to 7 days (1-2
step down if well-controlled	Step 2. Step up until well-	mg/kg, daily max 60mg). If initial
for 3 consecutive months.	controlled.	visit, start at Step 2. Step up 1-2
Re-assess every 1-6 months.	Re-assess in 2-6 weeks.	steps using Stepwise Approach
	For side effects, consider	Guideline. Re-assess in 2 weeks.
	alternative treatment.	

Other Things to Consider at Every Visit:

- 1. Check Adherence to Medication Routine
- 2. Provide Asthma Care Plan, Educate on use of MDI and Spacers and check technique
- 3. Environmental Controls, Pets, Smoke, Perfume, Allergies, Respiratory Infections
- 4. Treat Comorbidities



Reviewers:

Created by	Department	Creation Date	Version Date
S. Dharia, Z. Arain, P. Peterson	Pediatric Pulmonology	12/2017	3/2022



Intermittent Asthma	Persistent Asthma: Daily Medications					
_	Step up as indicated, although address possible poor adherence to medication. Re-assess in 2 – 6 weeks Step down if well controlled, re-assess in 3 months. If remain well-controlled, re-assess every 1-6 months					
Step 1	Step 2	Step 3	Step 4	Step 5	Step 6	
	Preferred:	Preferred:	Preferred:	Preferred:	Preferred:	
PRN Short-acting beta- agonist	Daily Low-dose ICS and PRN SABA:	Daily Medium Dose ICS and PRN SABA:	Daily Medium-dose ICS plus LABA and PRN SABA:	Daily High dose ICS plus LABA and PRN SABA:	Daily High dose ICS plus LABA and PRN SABA:	
e.g., Albuterol	Flovent HFA	Flovent HFA	Should use combination product (Safety and efficacy not	(safety and efficacy not established in children <4years	(safety and efficacy not established in children <4 years)	
or	Fluticasone MDI (44 mcg) 2 puffs BID	Fluticasone (110mcg) 2 puffs BID	established in children < 4 years old)	old)	Symbicort Budesonide/Formoterol	
For recurrent wheeze* at conset of a respiratory liness, add short course	Pulmicort Respule Budesonide Inhaled Suspension	Pulmicort Respule Budesonide Inhaled Suspension	Symbicort Budesonide/Formoterol (80/4.5 mcg) 2 puffs BID	Symbicort Budesonide/Formoterol (160/4.5 mcg) 2 puffs BID	(160/4.5 mcg) 2 puffs BID	
daily ICS (7-10 days) and PRN SABA.	(0.25 mg) 1-2x daily or (0.50 mg) 1-2x daily	(0.5 mg) BID	Dulera	Dulera	Dulera Mometasone/Formoterol	
Recurrent	Asmanex HFA Mometasone	Asmanex HFA Mometasone (100mcg) 2 puffs BID	Mometasone/Formoterol (100 mcg) 2 puffs BID	Mometasone/Formoterol (200/5 mcg) 2 puffs BID	(200/5 mcg) 2 puffs BID	
wheeze defined as at least three	(50 mcg) 2 puffs BID		Advair HFA	Advair HFA	Advair Fluticasone/Salmeterol	
episodes of wheezing	Alternative:	Alternative:	Fluticasone/Salmeterol 115/21mcg 2 puffs BID	Fluticasone/Salmeterol (230/21) mcg 2 puffs BID	(230/21 mcg) 2 puffs BID	
triggered by apparent	Cromolyn Generic neb solution (20 mg) 1 ampule QID	Daily Low dose ICS plus LABA and PRN SABA:		Or	Plus:	
infection in their lifetime, or two episodes in the past year, no	Safety and efficacy not established<2 years	Advair HFA Fluticasone/Salmeterol (45/21 mcg) 2 puffs BID		Daily Medium doe ICS plus LABA and PRN SABA And	Cromolyn Generic neb solution (20 mg) 1 ampule QID	
symptoms between infections.	And PRN SABA	Dulera Mometasone/Formoterol		Cromolyn Generic neb solution (20 mg) 1 ampule QID	And/or Prednisone Oral	
- IIICCIOII3.		(50 mcg) 2 puffs BID		(20 mg/ 1 ampaic Qib	0.5 mg/kg every other day	
		Consider Pediatric Puli	 monary consultation at Step	2		
schedule Follow-up Care: Fr	equency of follow-up visits base		•	ionths, Steps 5-6 : Every 1-2 month	IS	

Poviouer

Created by	Department	Creation Date	Version Date
S. Dharia, Z. Arain, P. Peterson	Pediatric Pulmonology	12/2017	3/2022

Outpatient Asthma Management 0 – 4 Years Old



References:

2021 GINA Main Report - Global Initiative for Asthma - GINA (ginasthma.org)
Guidelines for the Diagnosis and Management of Asthma 2007 (EPR-3) | NHLBI, NIH

Reviewers:

Created by	Department	Creation Date	Version Date
S. Dharia, Z. Arain, P. Peterson	Pediatric Pulmonology	12/2017	3/2022